Journal article
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Abstract
PURPOSE: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a second-generation HMA, and carboplatin (G+C) against second-line chemotherapy in women with measurable or detectable platinum-resistant ovarian cancer.
PATIENTS AND METHODS: Patients received …
Authors
Oza AM; Matulonis UA; Secord AA; Nemunaitis J; Roman LD; Blagden SP; Banerjee S; McGuire WP; Ghamande S; Birrer MJ
Journal
Clinical Cancer Research, Vol. 26, No. 5, pp. 1009–1016
Publisher
American Association for Cancer Research (AACR)
Publication Date
March 1, 2020
DOI
10.1158/1078-0432.ccr-19-1638
ISSN
1078-0432
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAzacitidineCarboplatinDeoxycytidineDoxorubicinDrug Resistance, NeoplasmEpigenesis, GeneticFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPaclitaxelPatient SafetyPolyethylene GlycolsSurvival RateTopotecanTreatment OutcomeGemcitabine